AVNS, BKR and CAG have been added to the Zacks Rank #5 (Strong Sell) List on May 15th, 2026.
Explore Avanos Medical's (AVNS) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Avanos Medical tops Q1 revenue estimates on strong SNS growth, but margin pressure and PM&R weakness weigh on earnings and profitability.
| Health Care Equipment & Supplies Industry | Healthcare Sector | David C. Pacitti CEO | XMUN Exchange | US05350V1061 ISIN |
| US Country | 2,227 Employees | - Last Dividend | - Last Split | 21 Oct 2014 IPO Date |
Avanos Medical, Inc. is a pioneering medical technology company that plays a significant role in the global healthcare sector, providing advanced medical device solutions across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Initially known as Halyard Health, Inc., the company underwent a rebranding to Avanos Medical, Inc. in June 2018, signifying its evolution and dedication to innovation in the medical field. Since its inception in 2014, and headquartered in Alpharetta, Georgia, Avanos is committed to improving patient outcomes by focusing on reducing reliance on opioids through its range of medical devices and solutions, catering to various aspects of patient care including chronic care, surgical pain relief, and interventional pain management. The company's strategic direct marketing approach, alongside partnerships with third-party distributors, enables it to effectively reach hospitals, healthcare providers, facilities, and end-users, ensuring broad access to its products and services around the globe.
Avanos Medical, Inc. offers an extensive portfolio of products and services designed to enhance patient care and recovery across several key areas: